Tuberc Respir Dis. 2019 Jan;82(1):1-5.
Published online Mar 7, 2018. https://doi.org/10.4046/trd.2017.0101
On page 3, “The control group of patients with no mental disorders showed no differences from other groups in the frequency of serious neuropsychiatric side effects, which were observed in 13 of the 99 subjects in the varenicline group (1.3%), 22 of the 989 subjects in the bupropion group (2.2%), 25 of the 1,006 subjects in the nicotine patch group (2.5%), and 24 of the 999 subjects in the placebo group (2.4%).“ should be corrected as follows:
The control group of patients with no mental disorders showed no differences from other groups in the frequency of serious neuropsychiatric side effects, which were observed in 13 of the 990 subjects in the varenicline group (1.3%), 22 of the 989 subjects in the bupropion group (2.2%), 25 of the 1,006 subjects in the nicotine patch group (2.5%), and 24 of the 999 subjects in the placebo group (2.4%).